Business Trends– category –
-
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Beyond the Liver: Engineered LNPs Achieve Precision Cardiac Delivery for SCD1 Inhibitor Aramchol
PR Newswire Israel Overview Galmed, in collaboration with Barcode Nanotech, has developed a groundbreaking lipid nanoparticle (LNP) formulation that precisely redirects its SCD1 inhibitor, Aramchol, from liver hepatocytes to cardiac musc... -
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
BeOne Medicines Invests $300M in New Jersey Manufacturing Expansion, Boosting Biologic, Small Molecule, and ADC Production
Fierce Pharma USA Overview BeOne Medicines announced a $300 million investment to significantly expand its manufacturing facility in New Jersey. The Hopewell campus, opened in 2024, will evolve into a fully integrated manufacturing hub, ... -
LNP Innovation Revolutionizes RNA Delivery: Advancing Tissue-Specific Targeting and Immunoprofile Optimization
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) have established themselves as the most clinically validated and advanced platform for RNA drug delivery. LNPs critically protect nucleic acids from enzymatic degradation, facil... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the... -
Optometrists Crucial for Ophthalmic Management of ADC Patients, Understanding Individualized Monitoring Requirements
Optometry Times USA Overview An Optometry Times article underscores the critical role of optometrists in the ophthalmic management of cancer patients undergoing Antibody-Drug Conjugate (ADC) therapy. Given that each ADC agent has unique ... -
Nurix Therapeutics and Roche Secure HSR Clearance for Global Co-Development and Co-Commercialization Agreement of BTK Degrader Bexobrutideg
Nurix Therapeutics USA Overview Nurix Therapeutics announced HSR clearance for its global co-development and co-commercialization agreement with Roche for the BTK degrader bexobrutideg. Bexobrutideg is advancing in malignant hematology, ... -
Advances in Antibody-Drug Conjugate (ADC) Combination Therapy for Non-Small Cell Lung Cancer: Multi-Target Approaches with Trop-2, HER2, and More
PubMed USA Overview A PubMed review reports significant advances in Antibody-Drug Conjugate (ADC)-based combination therapy strategies for Non-Small Cell Lung Cancer (NSCLC). Focusing on diverse molecular targets such as Trop-2, HER2, HE... -
NIH Launches ‘TRDNT Challenge’ to Drive Development of Precision RNA-Targeting Therapeutics for Disease
NIH USA Overview The National Institutes of Health (NIH) has initiated Phase I of the 'Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge' to foster a new class of RNA-targeting technologies. This initiative aims to accel...
